Peluntamig

N/A

Report date: 2025/07/21 20:01:29
First In Class

Base Information

Drug NamePeluntamig
Drug Alias NamePT-217
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionDelta-like protein 3 inhibitorsCluster of differentiation 47 inhibitors
TargetsDelta-like protein 3Cluster of differentiation 47
Therapy Area/IndicationsNeuroendocrine Carcinoma of LungSolid tumoursProstatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPhanes Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFanenshi Pharmaceutical (Beijing) Co LtdPhanes Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeuroendocrine Carcinoma of LungSolid tumoursProstatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A